A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

At the annual conference of the European Society of Human Genetics in Milan, biologist Dr. Edwige Kasper from the University ...

Jacifusen was generally well tolerated and reversed disease progression in some people with ALS caused by mutations in the ...

Scientists sprinted to create personalized medicine for baby KJ powered by CRISPR, a powerful gene-editing technology that won the Nobel Prize five years ago.

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

As newborn screening and rapid DNA sequencing become routine, we are poised to catch and treat inherited diseases at their ...

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent ...

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to com ...

Growing up in rural Indiana, I had more animal friends than human ones. I raised ducks and geese, and enjoyed my time ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...